|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 950 F Street, NW |
Address2 | Suite 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31350-12
|
||||||||
|
6. House ID# 306540000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul J. Larsen, Deputy Compliance Officer & Assistant General Counsel |
Date | 10/20/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009: prescription drug importation
H.6947, Department of Homeland Security Appropriations Act, 2009 - Making appropriations for the Department of Homeland Security for the fiscal year ending September 30, 2009, and for other purposes: prescription drug importation
S.3181, Department of Homeland Security Appropriations Act, 2009: prescription drug importation
S.3182, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2009: Office of the United States Trade Representative (USTR) and related issues
S.3230, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2009: HHS budget, importation, comparative effectiveness, and Part D benefit issues
S.3289, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2009: FDA budget and importation issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Andrea |
Douglas |
|
|
|
Amy |
Efantis |
|
Legislative Director - Rep. Artur Davis |
|
Bryant |
Hall |
|
|
|
Valerie |
Jewett |
|
Legis. Director - Rep. Rodney Frelinghuysen |
|
Kendra |
Martello |
|
|
|
Brian |
Nagle |
|
|
|
Byron |
Patterson |
|
|
|
Mimi |
Kneuer |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Matt |
Sulkala |
|
Senior Legislative Assistant - Rep. Allen Boyd |
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Derrick |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007: patent settlements
H.R. 1908, Patent Reform Act of 2007: patent issues
H.R. 4279, Prioritizing Resources and Organization for Intellectual Property Act of 2007: enforcement
S. 316, Preserve Access to Affordable Generics Act: patent settlements
S. 522, Intellectual Property Rights Enforcement Act: anti-counterfeiting and enforcement
S. 1145, Patent Reform Act of 2007: patent issues
S.2317, Intellectual Property Enforcement Act of 2007: enforcement
S.3325, Prioritizing Resources and Organization for Intellectual Property Act of 2008: enforcement
S.3600, Patent Reform Act of 2008: patent reform and related issues
International intellectual property issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Natl Economic Council (NEC), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robert |
Filippone |
|
|
|
Alan |
Gilbert |
|
|
|
Bryant |
Hall |
|
|
|
Mimi |
Kneuer |
|
|
|
David |
Korn |
|
|
|
Hallie |
Maranchick |
|
|
|
Kendra |
Martello |
|
|
|
Byron |
Patterson |
|
|
|
Heather |
Strawn |
|
|
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Brian |
Toohey |
|
|
|
Derrick |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 380, Pharmaceutical Market Access and Drug Safety Act of 2007: importation
H.R. 1014, Heart Disease Education, Analysis Research, and Treatment for Women Act: reporting and analysis of patient data
H.R. 1038, Access to Life-Saving Medicine Act: follow-on biologics
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007: follow-on biologics
H.R. 3610, Food and Drug Import Safety Act of 2007: import safety
H.R. 5501, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008: public health
H.R. 5629, Pathway for Biosimilars Act: follow-on biologics
H.R. 5683, The Government Accountability Office Act: disclosure of data
H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008: anti-counterfeiting
H.R. 6151, Responsibility in Drug and Device Advertising Act of 2008: direct-to-consumer drug advertising
H.R. 6353, Ryan Haight Online Pharmacy Consumer Protection Act of 2008: on-line pharmacy issues
H.R. 6378, Strengthening of FDA Integrity Act of 2008: debarment
H.R. 6381, Medical Device Safety Act of 2008: preemption issues
H.R. 6388 The Government Accountability Office Improvement Act of 2008: disclosure of data
H.R. 6432, Animal Drug User Fee Amendments of 2008: technical corrections to FDAAA
H.R. 6820, Water Assessment and Treatment Evaluation Research Study Act of 2008: pharmaceuticals in drinking water and human health
S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007: importation
S. 334, Healthy Americans Act: non-interference
S. 623, Access to Life-Saving Medicine Act: follow-on biologics
S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs
S. 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics
S. 2663, CPSC Reform Act: importation
S. 2731, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008: public health
S. 3046, Access, Compassion, Care, and Ethics for Seriously Ill Patients Act (ACCESS Act): access to investigational drugs and related issues
S. 3398, Medical Device Safety Act of 2008: preemption issues
S. 3409, Drug and Device Accountability Act of 2008: import safety
S. 3560, QI Program Supplemental Funding Act of 2008: antibiotic exclusivity provisions
S. 3633, Transparency in Drug Labeling Act: country of origin labeling for drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
Amy |
Efantis |
|
Legislative Director - Rep. Artur Davis |
|
Alan |
Gilbert |
|
|
|
Bryant |
Hall |
|
|
|
Lauryl |
Jackson |
|
|
|
Mimi |
Kneuer |
|
|
|
David |
Korn |
|
|
|
Hallie |
Maranchick |
|
|
|
Kendra |
Martello |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Byron |
Patterson |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Heather |
Strawn |
|
|
|
Matt |
Sulkala |
|
Senior Legislative Assistant - Rep. Allen Boyd |
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Jennifer |
Van Meter |
|
|
|
Derrick |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues
H.R. 758, Price Disclosure Regarding Treatment of Breast Cancer: transparency
H.R. 1424, Paul Wellstone Mental Health and Addiction Equity Act of 2007: Medicaid rebate
H.R. 2184, Enhanced Health Care Value for All Act of 2007: comparative effectiveness
H.R. 3162, Children's Health and Medicare Protection Act of 2007: Medicaid rebate
H.R. 4854, False Claims Act Correction Act of 2007: liability issues
H.R. 5605, Physician Payments Sunshine Act of 2008: transparency issues
H.R. 5683, The Government Accountability Office Act: disclosure of data
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008: comparative effectiveness, federal upper limit for Medicaid pharmacy reimbursement, electronic prescribing, Part D data disclosure, and other issues
H.R. 6388 The Government Accountability Office Improvement Act of 2008: disclosure of data
H.R. 6684, Medicare Prescription Drug Cost Equalization Act: Part D issues
H.R. 6752, The Independent Drug Education and Outreach Act of 2008: direct to physician marketing
S. 3, Medicare Prescription Drug Price Negotiation Act of 2007: Part D issues
S. 558, Mental Health Parity Act of 2007: health insurance issues
S. 2029, Physician Payments Sunshine Act of 2007: transparency issues
S. 2041, False Claims Act Correction Act of 2007: liability issues
S.3101, Medicare Improvements for Patients and Providers Act of 2008: comparative effectiveness, federal upper limit for Medicaid pharmacy reimbursement, electronic prescribing, Part D data disclosure, and other issues
S. 3118, Preserving Access to Medicare Act of 2008: electronic prescribing, Part D data disclosure, and other issues
S. 3396, The Independent Drug Education and Outreach Act of 2008: direct to physician marketing
S. 3408, Comparative Effectiveness Research Act of 2008: comparative effectiveness
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Congressional Budget Office (CBO), Medicare Payment Advisory Commission (MedPAC), Agency for Health Care Policy & Research
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Bergman |
|
|
|
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
Andrea |
Douglas |
|
|
|
Amy |
Efantis |
|
Legislative Director - Rep. Artur Davis |
|
Alan |
Gilbert |
|
|
|
Lauryl |
Jackson |
|
|
|
Ann |
Kaplan |
|
|
|
Mimi |
Kneuer |
|
|
|
Hallie |
Maranchick |
|
|
|
Thomas |
Moore |
|
|
|
Byron |
Patterson |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Heather |
Strawn |
|
|
|
Billy |
Tauzin |
|
|
|
Steve |
Tilton |
|
|
|
Jennifer |
Van Meter |
|
|
|
Derrick |
White |
|
|
|
Michael |
Woody |
|
Professional Staff - Senate HELP Committee |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3920, Trade and Globalization Assistance Act of 2007: trade adjustment assistance issues
H.R. 5501, President's Emergency Plan For AIDS Relief (PEPFAR): intellectual property, access to medicines and public health
H.R. 6180, Trade Reform, Accountability, Development, and Employment Act of 2008 (TRADE Act of 2008): intellectual property
S. 1848, Trade and Globalization Adjustment Assistance Act of 2007: trade adjustment assistance issues
S.2731, President's Emergency Plan For AIDS Relief (PEPFAR): intellectual property, access to medicines and public health
S.3083, Trade Reform, Accountability, Development, and Employment Act of 2008 (TRADE Act of 2008): intellectual property
Colombia Free Trade Agreement: intellectual property, market access and public health
Korea Free Trade Agreement: intellectual property, market access and public health Implementation of
Peru Free Trade Agreement: intellectual property, market access and public health
World Trade Organization intellectual property enforcement issues
International market access and intellectual property issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), State - Dept of (DOS), Commerce - Dept of (DOC), Natl Security Council (NSC), Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robert |
Filippone |
|
|
|
Mimi |
Kneuer |
|
|
|
Billy |
Tauzin |
|
|
|
Brian |
Toohey |
|
|
|
Byron |
Patterson |
|
|
|
Thomas |
Moore |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.phrma.org/about_phrma/member_company_list/members/
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |